168 related articles for article (PubMed ID: 35851929)
1. Giant prolactinoma in children and adolescents: a single-center experience and systematic review.
Kumar S; Sarathi V; Lila AR; Sehemby M; Memon SS; Karlekar M; Sankhe S; Patil VA; Shah N; Bandgar T
Pituitary; 2022 Dec; 25(6):819-830. PubMed ID: 35851929
[TBL] [Abstract][Full Text] [Related]
2. Giant prolactinoma in Asian-Indians: A single-center experience from Western India.
Kumar S; Memon SS; Lila AR; Sarathi V; Sehemby M; Karlekar M; Sankhe S; Thakkar H; Patil VA; Shah N; Bandgar T
Ann Endocrinol (Paris); 2023 Dec; 84(6):711-718. PubMed ID: 37866429
[TBL] [Abstract][Full Text] [Related]
3. Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients.
Salenave S; Ancelle D; Bahougne T; Raverot G; Kamenický P; Bouligand J; Guiochon-Mantel A; Linglart A; Souchon PF; Nicolino M; Young J; Borson-Chazot F; Delemer B; Chanson P
J Clin Endocrinol Metab; 2015 Mar; 100(3):1177-86. PubMed ID: 25532043
[TBL] [Abstract][Full Text] [Related]
4. Predictors of Chronic LH-Testosterone Axis Suppression in Male Macroprolactinomas With Normoprolactinemia on Cabergoline.
Sehemby M; Lila AR; Sarathi V; Shah R; Sankhe S; Jaiswal SK; Ramteke-Jadhav S; Patil V; Shah N; Bandgar T
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32942295
[TBL] [Abstract][Full Text] [Related]
5. Giant prolactinomas, a detailed analysis of 196 adult cases.
Lisa B; Arno V; Christophe B; Heyning Paul V; Carlien H
Pituitary; 2023 Oct; 26(5):529-537. PubMed ID: 37544978
[TBL] [Abstract][Full Text] [Related]
6. Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis.
Hoffmann A; Adelmann S; Lohle K; Claviez A; Müller HL
Eur J Pediatr; 2018 Jan; 177(1):125-132. PubMed ID: 29168011
[TBL] [Abstract][Full Text] [Related]
7. MANAGEMENT AND OUTCOMES OF GIANT PROLACTINOMA: A SERIES OF 71 PATIENTS.
Hamidi O; Van Gompel J; Gruber L; Kittah NE; Donegan D; Philbrick KA; Koeller KK; Erickson D; Natt N; Nippoldt TB; Young WF; Bancos I
Endocr Pract; 2019 Apr; 25(4):340-352. PubMed ID: 30995432
[No Abstract] [Full Text] [Related]
8. THE EFFECT OF RALOXIFENE ON SERUM PROLACTIN LEVEL IN PATIENTS WITH PROLACTINOMA.
Choudhary C; Hamrahian AH; Bena JF; Recinos P; Kennedy L; Dobri G
Endocr Pract; 2019 Jul; 25(7):684-688. PubMed ID: 30865525
[No Abstract] [Full Text] [Related]
9. Predictors of the Response to Dopaminergic Therapy in Patients With Prolactinoma.
Hage C; Salvatori R
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32930718
[TBL] [Abstract][Full Text] [Related]
10. Discrimination of prolactinoma from hyperprolactinemic non-functioning adenoma.
Hong JW; Lee MK; Kim SH; Lee EJ
Endocrine; 2010 Feb; 37(1):140-7. PubMed ID: 20963563
[TBL] [Abstract][Full Text] [Related]
11. T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists.
Burlacu MC; Maiter D; Duprez T; Delgrange E
Endocrine; 2019 Feb; 63(2):323-331. PubMed ID: 30267354
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of multimodal therapy for giant prolactinomas.
Andujar-Plata P; Villar-Taibo R; Ballesteros-Pomar MD; Vidal-Casariego A; Pérez-Corral B; Cabezas-Agrícola JM; Álvarez-Vázquez P; Serramito R; Bernabeu I
Endocrine; 2017 Jan; 55(1):231-238. PubMed ID: 27704480
[TBL] [Abstract][Full Text] [Related]
13. Proportion and predictors of Hypogonadism Recovery in Men with Macroprolactinomas treated with dopamine agonists.
Al Dahmani KM; Almalki MH; Ekhzaimy A; Aziz F; Bashier A; Mahzari MM; Beshyah SA
Pituitary; 2022 Aug; 25(4):658-666. PubMed ID: 35793046
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
15. A rare case of a giant prolactinoma with atypical histological features: 5 years of follow-up.
Vasilakis IA; Paltoglou G; Gavra M; Charmandari E
Hormones (Athens); 2022 Jun; 21(2):323-327. PubMed ID: 35143036
[TBL] [Abstract][Full Text] [Related]
16. Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment.
Ribeiro RS; Abucham J
Eur J Endocrinol; 2009 Jul; 161(1):163-9. PubMed ID: 19359408
[TBL] [Abstract][Full Text] [Related]
17. Clinical, Hormonal, and Neuroradiological Characteristics and Therapeutic Outcomes of Prolactinomas in Children and Adolescents at a Single Center.
Yang A; Cho SY; Park H; Kim MS; Kong DS; Shin HJ; Jin DK
Front Endocrinol (Lausanne); 2020; 11():527. PubMed ID: 32849307
[No Abstract] [Full Text] [Related]
18. [Selection of management tactics in treatment of giant prolactin-secreting pituitary adenomas].
Astaf'eva LI; Kadashev BA; Kalinin PL; Kutin MA; Faĭzullaev RB; Sidneva IuG; Tenedieva VD; Tropinskaia OF
Zh Vopr Neirokhir Im N N Burdenko; 2009; (2):23-8; discussion 28-9. PubMed ID: 19569545
[TBL] [Abstract][Full Text] [Related]
19. Broad clinical spectrum and diverse outcomes of prolactinoma with pediatric onset: medication-resistant and recurrent cases.
Kim YM; Seo GH; Kim YM; Choi JH; Yoo HW
Endocr J; 2018 Mar; 65(3):307-315. PubMed ID: 29279457
[TBL] [Abstract][Full Text] [Related]
20. Resistant prolactinomas: a case series of 26 patients.
Eshkoli T; Fraenkel M; Zaid D; Cohen D; Yoel U; Tsvetov G; Gorshtein A; Goldbart A; Greenman Y; Shimon I
Endocrine; 2022 Aug; 77(2):349-356. PubMed ID: 35604631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
